• Market Capitalisation market-capitalisation-info $5,146 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-278 Mln

BridgeBio Pharma Inc. (BBIO) Share Price

$28.84

As on 28-Nov-2023 16:09 EST

up-down-arrow $-0.95-3.19%

  • Prev Close info

    $29.79

  • Day's Openinfo

    $29.63

  • Today's Highinfo

    $30.01

  • Today's Lowinfo

    $28.39

  • Today's Volumeinfo

    1,272,889

  • 52 Week rangeinfo

    $6.64 - 36.36

Please wait...

BridgeBio Pharma Inc. (BBIO) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
BridgeBio Pharma (BBIO)
278.48 18.00 0.87 236.13 -16.27 -- --
S&P BSE Sensex*
10.91 5.65 4.09 6.94 15.19 13.27 12.49
S&P Small-Cap 600#
-5.82 -5.34 -13.90 -6.30 5.30 2.98 5.53
As on 28-Nov-2023  |  *As on 01-Dec-2023  |  #As on 26-Oct-2023
2022
2021
2020
BridgeBio Pharma (BBIO)
-54.32 -76.54 102.88
S&P Small-Cap 600
-17.42 25.27 9.57
S&P BSE Sensex
4.44 21.99 15.75

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

BridgeBio Pharma Inc. (BBIO) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of BridgeBio Pharma Inc. (BBIO)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of BridgeBio Pharma Inc. (BBIO)

        Co-Founder, Pres, CEO & Director

        Dr. Neil Kumar Ph.D.

        Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director

        Dr. Charles J. Homcy M.D.

        Headquarters

        Palo Alto, CA

        FAQs for BridgeBio Pharma Inc. (BBIO)

        The total asset value of BridgeBio Pharma Inc. (BBIO) stood at $ 757 Mln as on 30-Sep-23

        The share price of BridgeBio Pharma Inc. (BBIO) is $28.84 (NASDAQ) as of 28-Nov-2023 16:09 EST. BridgeBio Pharma Inc. (BBIO) has given a return of -16.27% in the last 3 years.

        BridgeBio Pharma Inc. (BBIO) has a market capitalisation of $ 5,146 Mln as on 24-Nov-2023. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of BridgeBio Pharma Inc. (BBIO) is 123.68 times as on 24-Nov-2023, a 47.69% premium to its peers’ median range of 2.54 times.

        Since, TTM earnings of BridgeBio Pharma Inc. (BBIO) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the BridgeBio Pharma Inc. (BBIO) and enter the required number of quantities and click on buy to purchase the shares of BridgeBio Pharma Inc. (BBIO).

        BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

        The CEO & director of Dr. Neil Kumar Ph.D.. is BridgeBio Pharma Inc. (BBIO), and CFO & Sr. VP is Dr. Charles J. Homcy M.D..

        The promoters of BridgeBio Pharma Inc. (BBIO) have pledged 0% of the total equity as on Jul-23.

        BridgeBio Pharma Inc. (BBIO) Ratios
        Return on equity(%)
        --
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        -1.43
        Dividend yield(%)
        0

        No, TTM profit after tax of BridgeBio Pharma Inc. (BBIO) was $-278 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $5,145.94 Mln
        • Revenue (TTM)revenue-information $9.43 Mln
        • Earnings (TTM) earning-information $-277.75 Mln
        • Cash date-information $505.21 Mln
        • Total Debt info $1,735.03 Mln
        • Insider's Holding 6.24%
        • Liquidity liquidity High
        • 52 Week range week-range $6.64 - 36.36
        • Shares outstanding share-outstanding 173,967,008
        • 6 Years Aggregate:

          CFO: $-1,747.86 Mln

          EBITDA: $-1,868.39 Mln

          Net Profit: $-2,038.94 Mln

        About The Company

        • IPO Date 27-Jun-2019
        • Co-Founder, Pres, CEO & Director Dr. Neil Kumar Ph.D.
        • Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director Dr. Charles J. Homcy M.D.
        • Listing key-listing NASDAQ: BBIO
        • Country United States
        • Headquarters headquarters Palo Alto, CA
        • Website website https://www.bridgebio.com
        • Business

          BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage...  development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon